HALOBETASOL PROPIONATE; TAZAROTENE - Generic Drug Details

What are the generic drug sources for halobetasol propionate; tazarotene and what is the scope of patent protection?

Halobetasol propionate; tazarotene is the generic ingredient in two branded drugs marketed by Bausch and Sun Pharma Canada, and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Halobetasol propionate; tazarotene has fifty-eight patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for HALOBETASOL PROPIONATE; TAZAROTENE

International Patents:	58
US Patents:	10
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HALOBETASOL PROPIONATE; TAZAROTENE
DailyMed Link:	HALOBETASOL PROPIONATE; TAZAROTENE at DailyMed

Recent Clinical Trials for HALOBETASOL PROPIONATE; TAZAROTENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dermatology Consulting Services, PLLC	Phase 4
Taro Pharmaceuticals USA	Early Phase 1
Icahn School of Medicine at Mount Sinai	Phase 4

See all HALOBETASOL PROPIONATE; TAZAROTENE clinical trials

Pharmacology for HALOBETASOL PROPIONATE; TAZAROTENE

Drug Class	Corticosteroid Retinoid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for HALOBETASOL PROPIONATE; TAZAROTENE

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

Paragraph IV (Patent) Challenges for HALOBETASOL PROPIONATE; TAZAROTENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUOBRII	Lotion	halobetasol propionate; tazarotene	0.01%/0.045%	209354	1	2020-06-11

US Patents and Regulatory Information for HALOBETASOL PROPIONATE; TAZAROTENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes			Y
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes			Y
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes			Y
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes			Y
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes			Y
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes

Expired US Patents for HALOBETASOL PROPIONATE; TAZAROTENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019

International Patents for HALOBETASOL PROPIONATE; TAZAROTENE

Country	Patent Number	Title	Estimated Expiration
Canada	2988577
Japan	2020519656	皮膚疾患を治療するための局所組成物および方法
South Korea	20180015281
Japan	2018526325	乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
Japan	2013542990
Mexico	346961

HALOBETASOL PROPIONATE; TAZAROTENE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Halobetasol Propionate and Tazarotene?

Halobetasol propionate and tazarotene are topical medications used mainly for dermatological conditions. Halobetasol propionate is a super-potent corticosteroid prescribed for eczema, psoriasis, and other inflammatory skin diseases. Tazarotene, a retinoid, treats acne vulgaris and psoriasis.

Market growth is influenced by rising prevalence of skin disorders, increased dermatological research, and expanding indications. The global dermatology market was valued at approximately $19 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7% from 2022 to 2027 ([1]).

Key driver: Growing demand for targeted therapies that improve patient outcomes. Rising incidence of psoriasis affects an estimated 125 million globally, according to the World Psoriasis Federation ([2]). Acne vulgaris impacts nearly 85% of adolescents and young adults ([3]).

Regulatory trends favor approval pathways for topical dermatological drugs, facilitating market entry. As patent protections expire, generic versions increase competition, pressuring prices.

How Is the Financial Trajectory Shaping for these Drugs?

Revenue Trends and Market Share

Both drugs possess significant revenue streams within their respective markets.

• Halobetasol Propionate: Marketed under multiple brands with annual sales in the U.S. exceeding $200 million (2019-2021). The drug faces competition from other potent corticosteroids like clobetasol or fluocinonide, impacting pricing power.

• Tazarotene: Achieves approximately $150 million in U.S. sales annually, with growth driven by expanding indications for psoriasis and acne. Development of formulations with enhanced bioavailability and fewer side effects aims to boost the pipeline.

Patent Status and Generic Competition

• Halobetasol Propionate: Original patents expired in most markets post-2017. Generic versions entered market, decreasing prices by 40-50%. Manufacturers seek new formulations or combination therapies to sustain revenue.

• Tazarotene: Patent expired around 2018 in the U.S., resulting in increased generic options. Although price erosion occurs, innovation in topical delivery systems maintains competitiveness.

R&D and Pipeline Developments

Research focuses on reducing adverse effects, improving patient adherence, and expanding indications. Recent approvals include combination formulations:

• Halobetasol and Tazarotene combinations for psoriasis are in early phases, aiming to enhance efficacy while minimizing side effects.

• Trials explore novel delivery systems, such as nanotechnology-enabled topical gels and patches, to improve drug penetration and patient compliance ([4]).

Market Entry Barriers

Regulatory approval hurdles, formulation development costs, and patent challenges limit rapid market entry for competitors. Insights suggest that the drugs' mature status and patent expirations have led to a consolidation of market share among leading pharmaceutical firms.

What Are the Financial Risks and Opportunities?

Risks

• Pricing pressure from generics and biosimilars decreases margins.

• Regulatory changes can impact approval pathways, especially regarding safety standards for potent corticosteroids and retinoids.

• Market saturation in mature indications diminishes revenue growth potential ([5]).

Opportunities

• Development of combination therapies can recapture market share.

• Introduction of novel formulations improves adherence and reduces side effects, potentially commanding premium pricing.

• Expansion into emerging markets offers growth prospects owing to increasing dermatology awareness and healthcare access.

Summary of Market Data and Financial Insights

Aspect	Details	Impact
Global dermatology market	$19 billion (2021), CAGR 7% (2022-2027)	Identifies the overall market size and growth rate
Leading indications	Psoriasis, acne	Strong demand for topical therapies
Patent status	Patents expired 2017-2018	Increased generic competition
Revenue estimates	Halobetasol: >$200 million/year; Tazarotene: ~$150 million/year	Demonstrates commercial scale
R&D pipeline	Combination drugs, novel delivery systems	Focus on maintaining market relevance

Key Takeaways

• The market for halobetasol propionate and tazarotene is mature, with growth driven primarily by expanding indications and formulations.
• Patent expirations have intensified price competition via generics, squeezing profit margins.
• Clinical pipeline innovations aim to differentiate products through improved safety, efficacy, and convenience.
• Emerging markets present a growth avenue amid mature markets facing saturation.
• Regulatory and patent landscapes will continue to influence market dynamics and profitability.

FAQs

1. How does patent expiration influence the profitability of halobetasol propionate and tazarotene?
Patent expiration opens markets to generic competitors, significantly reducing prices and margins. Companies adapt by developing new formulations or combinations to sustain revenue.

2. What factors are key to expanding the market for these drugs?
Development of combination therapies, improved formulations, and expansion into emerging markets drive growth potential.

3. Are there significant safety concerns affecting the market?
Yes. Potent corticosteroids like halobetasol have risks of skin atrophy and systemic absorption. Tazarotene may cause irritation and teratogenicity, influencing prescribing patterns.

4. What role does R&D play in the future of these drugs?
R&D aims to create formulations with enhanced safety profiles, better patient adherence, and broader indications, sustaining product relevance.

5. How does the competitive landscape look for new entrants?
Barriers include regulatory requirements, patent hurdles, and established market players. Innovation in delivery methods offers opportunities for differentiation.

---

Sources:

[1] Grand View Research, "Dermatology Market Size, Share & Trends," 2022.
[2] World Psoriasis Federation, "Global Psoriasis Statistics," 2021.
[3] American Academy of Dermatology Association, "Acne Vulgaris Facts," 2020.
[4] ClinicalTrials.gov, "Recent Topical Drug Delivery System Trials," 2022.
[5] IQVIA, "Pharmaceutical Market Insights," 2022.